The high abundance of immunosuppressive, tumor-associated macrophages limits the efficacy of treatments against hepatocellular carcinoma. Here, the authors develop a nanoplatform for the co-delivery of FSP1 inhibitor and sorafenib that simultaneously targets tumor cells and M2-like macrophages, inducing ferroptosis and boosting anti-tumor immune responses in preclinical mouse models.
- Chuanyu Tang
- Cheng He
- Chihua Fang
